Opus Genetics Q2 Cash at $88.8M, BEST1 Data Due September; Five Gene Therapies Advancing
IRD has more than doubled off its 52-week low of $1.04.
Summary
Opus Genetics reported Q2 2026 financials with $88.8M in cash, funding operations into 2029. The key catalyst is OPGx-BEST1 Cohort 1 topline data expected the second week of September 2026. Enrollment in the LCA5 registrational trial is complete, with dosing starting Q4 2026 and data by end of 2027. Three additional programs—RDH12, MERTK, and RHO—are advancing toward clinical testing over the next 18 months. This follows the June R&D Science Forum that outlined the fully funded pipeline. The cash position supports multiple data readouts and potential Priority Review Vouchers, reducing near-term dilution risk. Q2 net loss was $16.9M, with R&D spend of $12.5M reflecting active trial execution.
At the time of this announcement, IRD was trading at $3.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $312.1M. The 52-week trading range was $1.04 to $5.81. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.